Therapeutic effectiveness of rituximab in a patient with unresponsive autoimmune pulmonary alveolar proteinosis

Keyphrases

• Therapeutic Effectiveness 100%
• Granulocyte Colony-stimulating Factor (G-CSF) 100%
• Rituximab 100%
• Pulmonary Alveolar Proteinosis 100%
• Autoimmune Pulmonary Alveolar Proteinosis 100%
• Whole Lung Lavage 66%
• Growth Factors 33%
• Standard of Care 33%
• Autoimmune Disease 33%
• Patient Condition 33%
• Symptomatic Patients 33%
• High-flow Oxygen 33%
• Chest X-ray 33%
• Hypoxemia 33%
• Room Air 33%
• Dyspnea 33%
• Oxygen Therapy 33%
• Partial Remission 33%
• Alveoli 33%
• Supplemental Oxygen 33%
• Anti-CD20 Antibody 33%
• Lung Surfactant 33%
• Air Saturation 33%
• Rare Lung Diseases 33%
• Carbon Monoxide Diffusing Capacity 33%

Medicine and Dentistry

• Rituximab 100%
• Lung Alveolus Proteinosis 100%
• Granulocyte Macrophage Colony Stimulating Factor 75%
• Lung Lavage 50%
• Autoimmune Disease 25%
• Carbon Monoxide 25%
• Hypoxemia 25%
• Thorax Radiography 25%
• Growth Factor 25%
• Dyspnea 25%
• Oxygen Therapy 25%
• Case History 25%
• Rare Lung Disease 25%
• Lung Diffusion Capacity 25%
• CD20 Antibody 25%
• Pulmonary Surfactant 25%

Immunology and Microbiology

• Rituximab 100%
• Pulmonary Alveolar Proteinosis 100%
• Granulocyte Macrophage Colony-Stimulating Factor 75%
• Growth Factor 25%
• Autoimmune Disease 25%
• CD20 Antibody 25%
• Lung Diffusion Capacity 25%
• Immunology 25%